DE602006017507D1 - Synthese von ccr5 rezeptor antagonisten - Google Patents

Synthese von ccr5 rezeptor antagonisten

Info

Publication number
DE602006017507D1
DE602006017507D1 DE602006017507T DE602006017507T DE602006017507D1 DE 602006017507 D1 DE602006017507 D1 DE 602006017507D1 DE 602006017507 T DE602006017507 T DE 602006017507T DE 602006017507 T DE602006017507 T DE 602006017507T DE 602006017507 D1 DE602006017507 D1 DE 602006017507D1
Authority
DE
Germany
Prior art keywords
synthesis
receptor antagonists
ccr5 receptor
ccr5
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006017507T
Other languages
English (en)
Inventor
Wenxue Wu
Sa Bosco D
Feng Liang
Loc Thanh Tran
William Leong
Vilas Dahanukar
Ilia A Zavialov
Cecilia Proietti
Shannon Zhao
Hong-Chang Lee
Yi Liu
Hoa N Nguyen
Xiongwei Shih
Man Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602006017507D1 publication Critical patent/DE602006017507D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602006017507T 2005-01-06 2006-01-05 Synthese von ccr5 rezeptor antagonisten Active DE602006017507D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64190005P 2005-01-06 2005-01-06
PCT/US2006/000262 WO2006074270A2 (en) 2005-01-06 2006-01-05 Synthesis of ccr5 receptor antagonists

Publications (1)

Publication Number Publication Date
DE602006017507D1 true DE602006017507D1 (de) 2010-11-25

Family

ID=36571985

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017507T Active DE602006017507D1 (de) 2005-01-06 2006-01-05 Synthese von ccr5 rezeptor antagonisten

Country Status (13)

Country Link
US (2) US7728135B2 (de)
EP (1) EP1833817B1 (de)
JP (1) JP2008526863A (de)
CN (1) CN101137646A (de)
AR (1) AR054422A1 (de)
AT (1) ATE484500T1 (de)
CA (1) CA2594114A1 (de)
DE (1) DE602006017507D1 (de)
HK (1) HK1102303A1 (de)
MX (1) MX2007008280A (de)
SG (1) SG158861A1 (de)
WO (1) WO2006074270A2 (de)
ZA (1) ZA200705524B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011722A (es) 2004-04-13 2007-01-25 Incyte Corp Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina.
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
BR112013032911A2 (pt) 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida
CN103804445B (zh) * 2013-12-30 2016-01-13 广州自远生物科技有限公司 一种改进的乙酰异戊酰泰乐菌素的制备方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO2002079194A1 (en) * 2001-03-29 2002-10-10 Schering Corporation Ccr5 antagonists useful for treating aids

Also Published As

Publication number Publication date
EP1833817A2 (de) 2007-09-19
WO2006074270A3 (en) 2007-10-04
WO2006074270A2 (en) 2006-07-13
EP1833817B1 (de) 2010-10-13
HK1102303A1 (en) 2007-11-16
CN101137646A (zh) 2008-03-05
AR054422A1 (es) 2007-06-27
ZA200705524B (en) 2008-09-25
US7728135B2 (en) 2010-06-01
US20060258863A1 (en) 2006-11-16
SG158861A1 (en) 2010-02-26
MX2007008280A (es) 2007-09-07
CA2594114A1 (en) 2006-07-13
JP2008526863A (ja) 2008-07-24
ATE484500T1 (de) 2010-10-15
US20100036125A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
ATE486853T1 (de) Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten
CY2017008I2 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
DE602005021258D1 (de) Biphenylverbindungen geeignet für die Synthese von Muscarinrezeptorantagonisten
DE602006012450D1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE452886T1 (de) Chemokinrezeptorantagonisten
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE500249T1 (de) Synthese von himbacinanaloga
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
DE602007010010D1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
ATE462688T1 (de) Diarylsulfone als 5-ht2a-antagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE484500T1 (de) Synthese von ccr5 rezeptor antagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
DE602006006853D1 (de) Synthese von neuem Dihydrobenzoxazin
ATE402145T1 (de) Synthese von pyrrol-2-carbonsäurenitrilen
ATE479663T1 (de) Stereoselektive synthese von (s)-1-methyl-3- phenylpiperazin
DE602005007719D1 (de) Antagonisten des opioidrezeptors